A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

Indian J Pediatr. 2019 Dec;86(12):1157. doi: 10.1007/s12098-019-03069-1. Epub 2019 Sep 13.

Authors

Nagehan Aslan¹, Dincer Yildizdas², Yasemin Coban², Ozden Ozgur Horoz², Gulen Gul Mert³, Neslihan Ozcan³

Affiliations

¹ Department of Pediatrics, Division of Pediatric Critical Care Medicine, Faculty of Medicine, Cukurova University, Adana, Turkey. [email protected].
² Department of Pediatrics, Division of Pediatric Critical Care Medicine, Faculty of Medicine, Cukurova University, Adana, Turkey.
³ Department of Pediatrics, Division of Pediatric Neurology, Faculty of Medicine, Cukurova University, Adana, Turkey.

PMID: 31520312
DOI: 10.1007/s12098-019-03069-1

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Humans
Infant
Male
Muscular Atrophy, Spinal
Oligonucleotides / administration & dosage
Oligonucleotides / adverse effects*
Thrombocytosis / drug therapy*
Thrombocytosis / physiopathology
Thrombosis

Substances

Anti-Bacterial Agents
Oligonucleotides
nusinersen